Key Highlights

● Regeneron closed as the S&P 500's top gainer on Friday, October 30, 2026.

● Q3 Revenue of $5.12 billion beat the $4.54 billion analyst forecast.

● Non-GAAP Earnings Per Share of $20.07 topped the $16.24 consensus.

● Health care stocks hit a record high as investors rotated into defensives.

Regeneron Pharmaceuticals (NASDAQ:REGN) soared on Friday, October 30, 2026, closing as the top gainer in the S&P 500, according to market data. The rally came as the broader market suffered its worst session since June, which made the biotech's climb stand out even more sharply against a screen full of red.

The catalyst was a third-quarter report that left forecasts far behind. Regeneron posted revenue of $5.12 billion, well above the $4.54 billion analysts had expected. Non-GAAP earnings per share came in at $20.07, against a consensus estimate of $16.24. Both lines marked a decisive beat for a company that has long relied on its eye-disease, immunology and oncology franchises.

More than just the headline numbers

The quarter came with additional good news. According to market data, Regeneron also cited $1 billion in upfront payments tied to an expanded deal with Sanofi (NASDAQ:SNY), its longtime partner, along with a Food and Drug Administration approval for a product called Pasatru. Market reports said that the company raised its full-year outlook.

Sanofi, the French drugmaker that shares the expanded alliance, had its own strong day. A market headline said Sanofi beat third-quarter expectations and raised its 2026 sales forecast, giving both partners a lift in the same session.

Reports differed on the size of Regeneron's move during the day, with intraday readings showing a smaller gain than the final close. By the bell, however, the shares had built on their advance and stood at the very top of the benchmark.

Health care as a safe harbor

Regeneron's surge fit a wider pattern. Health care stocks hit a record high on Friday, according to market data, as investors pulled money out of chips, artificial intelligence names and megacap technology and moved it into defensive corners of the market. Energy, consumer staples, utilities and health care all rose, and six of the 11 S&P 500 sectors finished higher.

That rotation could not hold up the major indexes. The S&P 500 fell 140.32 points to 7,580.07, the Dow Jones Industrial Average dropped 572.25 points to 51,770.31, and the Nasdaq Composite tumbled 747.73 points to 25,437.00, its worst day since June 5. The Russell 2000 slid 47.37 points to 2,811.84.

The damage started with Intel (NASDAQ:INTC), which plunged after a weak fourth-quarter revenue forecast and a cash-burn warning, setting off a rout across semiconductors. Amazon (NASDAQ:AMZN)'s results, which showed negative trailing free cash flow, and continued fallout from Alphabet (NASDAQ:GOOGL)'s record selloff on Thursday added to pressure on technology. Oil above $100 a barrel, a reported $6.3 billion hack at crypto exchange Binance and a Federal Reserve that markets now expect to raise rates in December rounded out a difficult backdrop.

Other drugmakers joined the advance. Gilead Sciences (NASDAQ:GILD) and AbbVie (NYSE:ABBV) rose after their own results, and Eli Lilly (NYSE:LLY), Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) reached 52-week highs as money flowed into the sector.

What to watch

Investors will now look for further detail on the expanded Sanofi arrangement and on the commercial rollout of the newly approved product. The raised full-year outlook will also come under scrutiny as analysts update their models after the quarter.

The wider calendar is busy. Apple (NASDAQ:AAPL) reports on Monday, November 2, the midterm elections fall on Tuesday, November 3, and the October jobs report arrives on Friday, November 6. Whether the shift into health care continues may depend on how those events shape the debate over technology spending and interest rates.